Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Schmid, S.; Siano, M.; Joerger, M.; Rodriguez, R.; Müller, J.; Früh, M.
• Is Part Of: Lung cancer. Volume 87:Issue 1(2015:Jan.)
• Page Start: 85
• Page End: 87
• Publication Date: 2015-01
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.11.008
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">First report of a patient with an advanced, V600E BRAF-mutated NSCLC re-responding to the BRAF inhibitor dabrafenib after progressing on vemurafenib.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Resensitization of BRAF dependent cells following temporary interruption of BRAF inhibition as possible explanation for successful rechallenge after a treatment break.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Lack of cross-resistance between dabrafenib and vemurafenib as an alternative possible explanation cannot be ruled out.</p> </list-item> </list> </p> </sec> </abstract>